Several sections within the Patient Protection and Affordable Care Act (PPACA) contain provisions that directly affect the bottom line of pharmaceutical companies. Of equal importance, but not as well known, are provisions with indirect impact; these will change the healthcare delivery system by changing how health insurance for virtually everyone is offered, funded, and managed.
This paper presents a review of these indirect changes, which are likely to affect how payors and providers value, manage, and use pharmaceuticals.